Stay updated on Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial
Sign up to get notified when there's something new on the Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial page.

Latest updates to the Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial page
- Check7 days agoChange DetectedThe revision in the history changes from v3.6.2 to v3.6.3, indicating a small system update to the page’s record history. No study data or visible content appears to be altered.SummaryDifference0.1%

- Check14 days agoChange DetectedThe page revision label was updated from v3.6.0 to v3.6.2, indicating a newer version of the page; this change updates the metadata shown in the history view without modifying the underlying study information.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedA recruitment-status update shows the study is completed and no longer recruiting participants. The history also adds a new revision tag v3.6.0 and removes the previous v3.5.5 tag, reflecting updates to the record version.SummaryDifference0.3%

- Check35 days agoChange DetectedA new Revision: v3.5.5 entry was added to the record history. The previous Revision: v3.5.4 entry was removed, indicating an update to the history tracking on the page.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page history now shows the latest site revision v3.5.4 being added and the previous revision v3.5.3 removed. This indicates a backend/maintenance update to the ClinicalTrials.gov page rendering rather than changes to the study record data.SummaryDifference0.1%

- Check78 days agoChange DetectedUpdated the displayed ClinicalTrials.gov interface/app revision label from **v3.5.2** to **v3.5.3**.SummaryDifference0.1%

Stay in the know with updates to Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy of PF-06650833, PF-06651600, and Tofacitinib in RA Clinical Trial page.